First promising data for a dual JAK/SYK inhibitor
“This is the first clinical study with ASN002, a novel JAK/SYK inhibitor” said Dr Robert Bissonnette of Innovaderm Research at the presentation of this Phase 1b trial .
According to Dr Bissonnette, ASN002 is an interesting molecule and somewhat different from other JAK inhibitors, because it also affects spleen tyrosine kinase (SYK). This intracellular kinase inhibits IL-17 signalling/CC chemokine ligand 20 production in keratinocytes, increases terminal differentiation of keratinocytes, and inhibits B-cell signalling, which plays a role in skin immunity. AS002 thus diminishes production of Th2 and Th22 cytokines. The dysregulation of Th2 and Th22 cytokine pathways are a hallmark of the pathogenesis of AD.
Although safety was the primary target of this trial there were also several efficacy targets. The 36 study participants represented the typical AD population with moderate-to-severe dise...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Biologics in psoriasis and new selective IL-23 blockers Next Article
New topical and systematic treatments »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.